By Caitlyn Romanski

On the weekend of September 26-28, 2026, research intern Michela Cadarso attended the American Association for Cancer Research’s (AACR) Conference on Pancreatic Cancer.

Traveling to San Diego, California, Cadarso presented her collaborative research alongside experts from across the field. Her poster, “Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma,” explored the potential of combining CDK9 inhibition with KRAS-directed therapy in patient-derived models of pancreatic ductal adenocarcinoma.

During the coference, Cadarso also had her research highlighted by SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

Congratulations, Michela!